Biofrontera AG (0DOL)

Profile

https://www.biofrontera.com

Biofrontera AG is a biopharmaceutical company specializing in the development, research, and commercialization of dermatological drugs, with a strong emphasis on photodynamic therapy (PDT) for skin conditions. Headquartered in Leverkusen, Germany, and founded in 1997, the company focuses on innovative treatments for sun-induced skin cancers and precursors, primarily through its lead product Ameluz, a topical gel used alongside BF-RhodoLED lamps to treat actinic keratoses, field cancerization, and squamous cell carcinoma on the face and scalp. Additional offerings include the RhodoLED XL lamp for multiple lesions and Belixos, a cosmetic for sensitive skin. Biofrontera AG operates in Europe, the United States, and internationally, holding centralized EU and UK approvals for its in-house developed therapies. It pursues portfolio expansion via partnerships, such as with Leo Pharma and Galenica, targeting growth in the European dermatology market while advancing label extensions and new formulations like propylene glycol-free Ameluz. Listed on the Frankfurt Stock Exchange's Prime Standard, Biofrontera AG plays a key role in addressing rising incidences of non-melanoma skin cancers driven by aging populations and lifestyle factors, positioning itself as an innovation leader in targeted skin health solutions.